Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome.
Brooks, J C, Roberts, N, Whitehouse, G et al. · The British journal of radiology · 2000 · DOI
Quick Summary
This study used brain imaging to examine a part of the brain called the hippocampus in people with ME/CFS and healthy controls. While the size of the hippocampus was normal in ME/CFS patients, a specific chemical marker called N-acetylaspartate was significantly lower in the right side of the hippocampus compared to healthy people. This suggests there may be subtle differences in how brain cells are functioning in ME/CFS, even when the brain structure looks normal.
Why It Matters
This is one of the earlier neuroimaging studies suggesting that ME/CFS may involve biochemical brain changes not visible on standard structural imaging. The finding of altered NAA—a marker of neuronal integrity—supports the hypothesis that ME/CFS has an organic neurobiological basis, which is important for legitimizing the condition and directing future research toward understanding brain metabolism in the disease.
Observed Findings
N-acetylaspartate concentration was significantly reduced in the right hippocampus of CFS patients compared to controls (p = 0.005)
Hippocampal volume was not significantly different between CFS patients and controls
Seven CFS patients were compared to ten healthy age-matched control subjects
The study used unbiased morphometric methods for volume measurement and proton MRS for neurochemical analysis
Inferred Conclusions
CFS may involve biochemical abnormalities in brain metabolism that are not reflected in structural brain changes
The hippocampus, a region involved in memory and stress response, may be affected at the neuronal level in CFS
Neurochemical markers like NAA could potentially be investigated further as biological indicators of CFS
Remaining Questions
What is the functional significance of reduced hippocampal NAA in relation to specific ME/CFS symptoms like cognitive impairment or memory problems?
Does NAA concentration correlate with disease severity, symptom duration, or patient outcomes?
Are other brain regions also affected by similar neurochemical changes, or is the hippocampus uniquely impacted?
What This Study Does Not Prove
This study does not prove that reduced hippocampal NAA causes ME/CFS symptoms, nor does it establish whether this difference is a cause, consequence, or marker of the disease. The small sample size and lack of correlation with specific symptoms mean these findings cannot be generalized to all ME/CFS patients or used for clinical diagnosis. Cross-sectional design prevents any conclusions about whether NAA levels change over time.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsNeuroimaging
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample